NEW YORK, May 11, 2023 /PRNewswire/ — Terran Biosciences (“Terran”), a biotech platform company dedicated to the development of transformational therapeutics for neurological and psychiatric diseases, has announced the publication of four PCT patent applications covering novel improvements to the empathogens methylone (also known as bk-MDMA or MDMC), ethylone, MDEA (also known as MDE), MDAI…


Previous articleCOMPASS Pathways Announces First Quarter 2023 Financial Results and Business Highlights
Next articleClearmind Medicine Announces IRB Approval to Conduct Clinical Trial on Alcohol Use Disorder